Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.44
- Piotroski Score 2.00
- Grade Buy
- Symbol (IPA)
- Company ImmunoPrecise Antibodies Ltd.
- Price $0.61
- Changes Percentage (13.7%)
- Change $0.07
- Day Low $0.55
- Day High $0.63
- Year High $2.60
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.42
- Trailing P/E Ratio -2.36
- Forward P/E Ratio -2.36
- P/E Growth -2.36
- Net Income $-27,177,000
Income Statement
Quarterly
Annual
Latest News of IPA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The next 'bipartisan border bill' needs to target the 600K migrant...
Kamala Harris supports a bipartisan immigration bill to address the border crisis, but Sen. Joni Ernst's "Be Gone Act" is proposed to deport migrant sex offenders. With a high number of criminal migra...
By New York Post | 1 day ago -
SIT Investment Associates Inc Reduces Stake in Nuveen New Jersey Quality Municipal Income Fund
SIT Investment Associates Inc reduced its stake in Nuveen New Jersey Quality Municipal Income Fund by 19.37%, selling 475,455 shares at $12.98 per share....
By Yahoo! Finance | 1 day ago -
B.C. election: Party leaders to participate in live TV debate | Globalnews.ca
B.C.'s party leaders to take part in a televised debate on Oct. 8 at 6:30 p.m., moderated by Shachi Kurl....
By Global News | 2 days ago
